
A conference preview highlights two-way interactions between dietary compounds and gut microbes, with implications for interpreting supplement claims.

On October 26, 2026, NutraIngredients previewed Dr. Victoria Selma’s planned IPC 2027 presentation on how dietary polyphenols and gut microbes influence each other. Selma’s central point was that existing microbial communities may help explain why people respond differently to the same polyphenol-rich dietary intervention.
The comparison in Selma’s account is with approaches centered on changing which microorganisms are present in the gut. Her proposed direction places more attention on microbial functions and the substances those microbes produce. In plain language, the question moves from “Which microbes are there?” toward “What are they doing?”
That distinction is important when interpreting the announcement. The coverage describes a shift in research emphasis rather than the overturning of a medical consensus that everyone responds alike. Selma’s argument builds on individual differences by asking how those differences affect the processing of dietary compounds.
In her comments to NutraIngredients, Selma described a future in which interventions might target particular microbial functions and metabolites. Metabolites are substances produced when compounds undergo chemical changes. Her emphasis is on understanding those processes in a given person rather than focusing only on the names of microorganisms.
This provides useful context for why gut communities differ from person to person. The question here is not simply whether communities differ, but whether their different capabilities help explain different responses to the same dietary input.
The central idea in the NutraIngredients preview is a two-way relationship. Dietary polyphenols may affect the microbial community already present in the gut. At the same time, those microbes can transform the compounds they encounter.
“Bidirectional” is the technical term for this relationship. It means the dietary compound is not the only active part of the story. The existing microbial community also participates in determining what happens to that compound.
The report describes several forms of microbial processing:
These examples make the research idea more concrete. An ingredient enters the picture, but microbial activity helps shape the substances produced afterward. Selma’s point is that the starting microbial community belongs in that explanation alongside the dietary compound itself.
This changes how an intervention can be described. Looking only at the ingredient leaves out the microbial processing highlighted in the report. Looking only at which microbes are present leaves out the question of what those organisms do with that ingredient.
NutraIngredients uses “microbial metabotypes” to describe functional differences that influence which metabolites people can produce and in what quantities. The term groups differences by microbial processing capability. It shifts attention toward the chemical work performed by a community rather than its membership alone.
For example, the research question is not simply whether a person consumes a particular compound. It also asks whether their microbial community can transform it into a given metabolite. Selma told NutraIngredients that these existing microbial differences may help explain different responses to the same polyphenol-rich intervention.
The distinction is between an input and a process. The input is the dietary compound. The process includes what the existing microbes do with it. Understanding both is the research aim described in the preview.
For a reader comparing products, the implication is that an ingredient label describes what is supplied. It does not describe the person’s microbial capacity to transform that ingredient. The reporting therefore gives a biological reason to question the assumption that an identical ingredient must produce an identical response.
Although the preview centers on polyphenols, it raises a relevant question for discussions of prebiotics and gut supplements: what evidence connects a product’s ingredient to the response being claimed? That question keeps the focus on the actual research rather than treating a microbiome-related explanation as a complete account of an outcome.
A useful distinction is between a mechanism and a measured result. A mechanism describes how something might happen. A measured result establishes what happened under the conditions studied. DigestGenius’s framework for assessing microbiome evidence helps readers keep those different kinds of claims separate.
The first constraint is the nature of the news itself. This is a conference preview, not a newly published clinical trial or a report of a completed presentation. NutraIngredients says Selma is scheduled to speak at IPC 2027 in Kraków, Poland. She is a senior research scientist and vice-director at CEBAS-CSIC in Spain.
The preview does not provide trial-level effect sizes for a particular supplement or dietary intervention. It therefore supplies no basis for estimating how much a product might change someone’s symptoms or other health outcomes. Those are different questions from whether microbial transformation occurs.
The examples involving urolithins and equol illustrate microbial transformation. They do not establish that every person who produces a given metabolite will receive a health benefit from a particular supplement. A chemical pathway is one part of the explanation, not the final clinical outcome.
The report also identifies appropriate safety frameworks as a challenge for future microbiome-targeted interventions. That matters because identifying a function to target and establishing a safe intervention are separate tasks. Selma’s forward-looking view should be read as a research direction rather than evidence that function-based interventions are established in routine care.
The metabotype framework described in the preview is not presented as a validated consumer test or a clinical treatment-selection tool. It does not establish a reliable way to select a particular prebiotic or supplement from a commercial microbiome report. Naming a functional difference is not the same as validating a decision based on it.
In separate NutraIngredients coverage, Nicola Segata of the University of Trento cautioned against treating one microbiome test as a long-term nutrition prescription. He said results need context about age and sex. BMI, medication and disease also matter to interpretation, and he noted that the abundance of a strain can vary with meals.
That coverage described a core research cohort of more than 34,000 U.S. and U.K. Zoe platform participants. It also reported that the research team had since sequenced data from more than 250,000 participants. These figures describe the reported research program, not a universally representative population or proof that sequencing predicts individual supplement responses.
Segata argued that more large-scale and long-term research is needed to connect sequencing with nutrition recommendations. He also said microbiome uniqueness makes a universal microbiome-modifying solution difficult to envisage. His comments place the personalization discussion in context without turning it into an established service for choosing products.
The practical value of this news is a better question, not a new shopping list: does the evidence describe microbial processing, or does it demonstrate a meaningful outcome? Keeping that distinction visible makes ingredient claims easier to assess without expecting everyone to respond identically.
For daily dietary choices, this preview is a reason to resist universal promises rather than to add restrictions or assume a supplement is necessary. It also offers no reason to assign oneself a metabotype. Questions about recurring digestive symptoms or personal supplement decisions belong with a qualified healthcare professional who can consider the wider situation.
The realistic direction is more precise research into individual responses. Until that work supports dependable personal recommendations, microbial function is best treated as an important part of the explanation, not a ready-made dietary prescription.
Deciding whether microbial metabolism should influence a supplement choice requires separating an interesting mechanism from evidence for that decision. DigestGenius addresses uncertainty about prebiotics and gut supplements through free articles and detailed learning resources on digestion and nutrition, helping adults understand where promising microbiome findings fit alongside established knowledge without prescribing a personal regimen.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.



Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog